[Third-line CPT-11 chemotherapy for gastric cancer cases of non-curative gastrectomy or recurrence].
BACKGROUND
There have been few case reports of 3rd-line chemotherapy for gastric cancer. So we reported the results of CPT-11 therapy as the 3rd-line chemotherapy for gastric cancer.


METHODS
549 cases underwent gastrectomy from Jan. 2004 to Aug. 2007 in our hospital. In 76 of these cases, which underwent non-curative resection or evidenced a recurrence until July 2009, were analyzed in this study. CPT -11 3rd-line chemotherapy was administered to 11 cases.


RESULTS
The mean survival time of non-curative or recurrent cases was 16.9 months. Mean survival times of the non-chemotherapy group, the group administered only 1st-line chemotherapy, the group administered until 3rd-line chemotherapy, the group administered 3rd-line chemotherapy were 7.9 , 11.3 , 21.4 and 28.9 months, respectively(p=0.000 ). Adverse effects occurred in 90.9% of 3rd-line CPT-11, however, all cases were categorized in GradeI.


CONCLUSIONS
The group administered 3rd-line chemotherapy survived the longest. It is probably correct to administer 3rd-line chemotherapy, if the patient maintains a good performance status.
Kawamura
Hideki
H
Department of Surgery, Sapporo Kosei Hospital.
Yokota
Ryoichi
R
Watarai
Hiroshi
H
Yokota
Kentaro
K
Tanioka
Toshiro
T
Tsunoda
Yoshihiko
Y
Masuko
Hiroyuki
H
Tanaka
Koichi
K
Yamagami
Hideki
H
Hata
Tsunetake
T
Okada
Kuniaki
K
Ishizu
Hiroyuki
H
Kondo
Yukifumi
Y
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005743:Gastrectomy; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate
D000970:Antineoplastic Agents; D000077146:Irinotecan; D002166:Camptothecin